X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs NATCO PHARMA - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA NATCO PHARMA ASTRAZENECA PHARMA/
NATCO PHARMA
 
P/E (TTM) x 161.6 16.0 1,010.6% View Chart
P/BV x 24.5 17.2 142.3% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 ASTRAZENECA PHARMA   NATCO PHARMA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
NATCO PHARMA
Mar-14
ASTRAZENECA PHARMA/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,285877 146.5%   
Low Rs634424 149.7%   
Sales per share (Unadj.) Rs189.6223.4 84.9%  
Earnings per share (Unadj.) Rs-0.231.1 -0.7%  
Cash flow per share (Unadj.) Rs3.840.3 9.5%  
Dividends per share (Unadj.) Rs05.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs68.6219.5 31.3%  
Shares outstanding (eoy) m25.0033.07 75.6%   
Bonus/Rights/Conversions -PA-  
Price / Sales ratio x5.12.9 173.9%   
Avg P/E ratio x-4,712.720.9 -22,516.1%  
P/CF ratio (eoy) x249.616.1 1,545.8%  
Price / Book Value ratio x14.03.0 471.9%  
Dividend payout %016.1 0.0%   
Avg Mkt Cap Rs m23,98821,504 111.6%   
No. of employees `0001.6NA-   
Total wages/salary Rs m1,6051,128 142.3%   
Avg. sales/employee Rs Th3,040.2NM-  
Avg. wages/employee Rs Th1,029.2NM-  
Avg. net profit/employee Rs Th-3.3NM-  
INCOME DATA
Net Sales Rs m4,7407,389 64.1%  
Other income Rs m92167 55.1%   
Total revenues Rs m4,8327,556 63.9%   
Gross profit Rs m-1301,793 -7.2%  
Depreciation Rs m101304 33.2%   
Interest Rs m0366 0.0%   
Profit before tax Rs m-1391,290 -10.8%   
Minority Interest Rs m046 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m5309 1.6%   
Profit after tax Rs m-51,027 -0.5%  
Gross profit margin %-2.724.3 -11.3%  
Effective tax rate %-3.723.9 -15.3%   
Net profit margin %-0.113.9 -0.8%  
BALANCE SHEET DATA
Current assets Rs m2,7263,681 74.1%   
Current liabilities Rs m2,4353,123 78.0%   
Net working cap to sales %6.17.6 81.3%  
Current ratio x1.11.2 95.0%  
Inventory Days Days7489 82.4%  
Debtors Days Days4159 69.5%  
Net fixed assets Rs m1,0357,685 13.5%   
Share capital Rs m50331 15.1%   
"Free" reserves Rs m9426,670 14.1%   
Net worth Rs m1,7167,259 23.6%   
Long term debt Rs m0955 0.0%   
Total assets Rs m4,15611,957 34.8%  
Interest coverage xNM4.5-  
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x1.10.6 184.6%   
Return on assets %-0.111.7 -1.1%  
Return on equity %-0.314.2 -2.1%  
Return on capital %020.7 0.0%  
Exports to sales %5.739.4 14.5%   
Imports to sales %6.55.7 113.4%   
Exports (fob) Rs m2702,908 9.3%   
Imports (cif) Rs m306421 72.7%   
Fx inflow Rs m3753,445 10.9%   
Fx outflow Rs m470703 66.9%   
Net fx Rs m-962,743 -3.5%   
CASH FLOW
From Operations Rs m-81,440 -0.6%  
From Investments Rs m-146-1,089 13.4%  
From Financial Activity Rs m862-353 -244.5%  
Net Cashflow Rs m709-1 -47,550.3%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 75.0 1.5 5,102.0%  
Indian inst/Mut Fund % 0.3 7.8 3.8%  
FIIs % 15.7 16.6 94.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 26.0 35.0%  
Shareholders   12,856 25,395 50.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   ABBOTT INDIA  ALKEM LABORATORIES  AJANTA PHARMA  PFIZER  DR. DATSONS LABS  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 207 Points Higher; Healthcare Stocks Witness Buying(Closing)

Indian share markets continued to trade in the green during the closing hours of the trading session and ended the day on a positive note.

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 212.1% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 32 m (down 212.1% YoY). Sales on the other hand came in at Rs 2 bn (up 35.1% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Is Franklin India Smaller Companies Fund Worth Your Money(Outside View)

Aug 2, 2018

Although positioned as a small cap fund, Franklin India Smaller Companies Fund has been investing a significant portion of its assets in mid-caps along with a nominal exposure to large caps.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Aug 14, 2018 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS